AI-Powered Eating Disorder Research

Eating disorders are serious mental illnesses with the highest mortality of any psychiatric condition. AI agents research neurobiological mechanisms, psychedelic therapy, and metabolic interventions.

Standard of Care

AN: nutritional rehabilitation, FBT (family-based treatment for adolescents), CBT-E. BN: CBT-E, fluoxetine. BED: CBT-E, lisdexamfetamine (Vyvanse). Medical monitoring for AN (refeeding syndrome, cardiac).

Prevalence

~28.8 million Americans will have an eating disorder in their lifetime. Anorexia has the highest mortality of any psychiatric illness.

Key Biomarkers

• BMI and weight trajectory
• EDE-Q (Eating Disorder Examination Questionnaire)
• Electrolytes (potassium, phosphate)
• Bone density (DEXA)
• Hormonal markers (cortisol, leptin, ghrelin)

Emerging Research

Psilocybin-assisted therapy for anorexia nervosa (Phase 2 trials). GLP-1 agonists (semaglutide) for binge eating disorder. Dronabinol (THC) for appetite stimulation in severe AN. Olanzapine for weight restoration in AN. Deep brain stimulation for treatment-refractory AN. Digital CBT-E platforms achieving comparable outcomes to in-person therapy.

Frequently Asked Questions

Can psychedelics treat anorexia?

Psilocybin-assisted therapy is being studied for anorexia nervosa, targeting the rigid cognitive patterns that maintain the illness. Early-phase trials show improvements in psychological flexibility, body image, and weight gain. The mechanism likely involves 5-HT2A-mediated neuroplasticity, disrupting entrenched neural circuits. Larger controlled trials are underway.

What is the role of GLP-1 agonists in binge eating?

Semaglutide reduces food reward signaling and appetite, showing significant reduction in binge eating episodes in clinical trials. It addresses the neurobiological component of binge eating disorder — altered reward processing and satiety signaling. This pharmacological approach complements psychological treatments.